Therapeutic Advances in Musculoskeletal Disease最新文献

筛选
英文 中文
Counting the costs: a nationwide study on healthcare use following an adalimumab biosimilar switch in >1300 inflammatory arthritis patients. 计算成本:在全国范围内对超过 1300 名炎症性关节炎患者更换阿达木单抗生物仿制药后的医疗保健使用情况进行研究。
IF 3.4 2区 医学
Therapeutic Advances in Musculoskeletal Disease Pub Date : 2024-10-16 eCollection Date: 2024-01-01 DOI: 10.1177/1759720X241289391
Hafsah Nabi, Rikke Ibsen, Michael Ibsen, Jakob Kjellberg, Merete Lund Hetland, Bente Glintborg
{"title":"Counting the costs: a nationwide study on healthcare use following an adalimumab biosimilar switch in >1300 inflammatory arthritis patients.","authors":"Hafsah Nabi, Rikke Ibsen, Michael Ibsen, Jakob Kjellberg, Merete Lund Hetland, Bente Glintborg","doi":"10.1177/1759720X241289391","DOIUrl":"10.1177/1759720X241289391","url":null,"abstract":"<p><strong>Background: </strong>In Denmark, cost savings motivate mandatory biosimilar switches. In 2018, patients switched from originator to biosimilar adalimumab, that is, to GP2017 in Eastern and to SB5 in Western Denmark. However, concerns were raised about additional costs covering, that is, an increased number of outpatient visits due to patient education, treatment monitoring, and patient concerns.</p><p><strong>Objectives: </strong>To investigate whether the switch led to increased total healthcare costs, defined as costs related to in- and outpatient contacts in hospitals and the primary sector and use of prescription medicine (excluding biological treatment).</p><p><strong>Design: </strong>Observational cohort study with geographical cluster pseudo-randomization.</p><p><strong>Methods: </strong>Patients with rheumatoid arthritis, psoriatic arthritis (PsA), and axial spondyloarthritis (AxSpA), who switched were identified in the nationwide DANBIO registry. Total healthcare costs 9 months before and after the switch were captured from the National Patient and Prescription registries. The difference between pre- and post-switch costs was estimated by a generalized estimation equations (GEE) model.</p><p><strong>Results: </strong>Overall, 1316 patients switched to GP2017 (<i>n</i> = 621) or SB5 (<i>n</i> = 695). Total healthcare costs were mainly driven by hospital costs. The monthly fluctuations of hospital costs 9 months before and after the switch were largely similar or decreased. In the adjusted analyses (GEE), hospital costs decreased after the switch (by approximately 15%) for GP2017 switchers, especially PsA (estimate = 0.83; 95% CI 0.75-0.92) and AxSpA patients (estimate = 0.85; 0.77-0.93), with no significant changes for SB5 switchers.</p><p><strong>Conclusion: </strong>We found no increase in total healthcare costs in 9 months following a nationwide mandatory adalimumab originator to biosimilar switch. Our findings were strengthened by similar results for GP2017 and SB5.</p>","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"16 ","pages":"1759720X241289391"},"PeriodicalIF":3.4,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11526192/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142558861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Computed tomography-current status and future directions for arthritis imaging. 计算机断层扫描--关节炎成像的现状和未来方向。
IF 3.4 2区 医学
Therapeutic Advances in Musculoskeletal Disease Pub Date : 2024-10-08 eCollection Date: 2024-01-01 DOI: 10.1177/1759720X241287373
Sevtap Tugce Ulas, Torsten Diekhoff
{"title":"Computed tomography-current status and future directions for arthritis imaging.","authors":"Sevtap Tugce Ulas, Torsten Diekhoff","doi":"10.1177/1759720X241287373","DOIUrl":"https://doi.org/10.1177/1759720X241287373","url":null,"abstract":"<p><p>Applications of computed tomography (CT) in arthritis imaging have rapidly expanded in recent years due to ongoing technical developments. Dual-energy CT (DECT) has become indispensable in clinical practice, particularly for diagnosing gouty arthritis and assessing bony structural changes. Technological innovations such as low-dose CT and state-of-the-art reconstruction algorithms reduce radiation exposure while maintaining image quality and short acquisition times. This review explores the growing role of CT in arthritis imaging. Recent innovations have extended DECT's utility beyond gout diagnosis to the detection of inflammatory changes in various arthritic conditions. Postprocessing techniques such as the generation of subtraction images and iodine maps provide valuable insights into tissue perfusion and inflammatory activity, crucial for arthritis management. DECT can distinguish calcium from uric acid crystals, facilitating the differential diagnosis of various crystal arthropathies in a variety of clinical settings. This ability is particularly valuable in distinguishing between different clinical conditions in patients with inflammatory joint changes within a single imaging examination. Moreover, the advent of four-dimensional CT promises a better assessment of dynamic joint instabilities and ligament injuries, especially in the wrist. Overall, DECT offers a comprehensive approach to arthritis imaging, from the detection of structural changes to the assessment of active inflammation in joints and tendons. Continuous advances in CT technology, including photon-counting CT, hold promise for further improving diagnostic accuracy and expanding the role of CT in arthritis imaging and therapy monitoring.</p>","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"16 ","pages":"1759720X241287373"},"PeriodicalIF":3.4,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11497529/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142508537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An optimal deep learning model for the scoring of radiographic damage in patients with ankylosing spondylitis. 强直性脊柱炎患者放射损伤评分的最佳深度学习模型。
IF 3.4 2区 医学
Therapeutic Advances in Musculoskeletal Disease Pub Date : 2024-10-07 eCollection Date: 2024-01-01 DOI: 10.1177/1759720X241285973
Yen-Ju Chen, Der-Yuan Chen, Haw-Chang Lan, An-Chih Huang, Yi-Hsing Chen, Wen-Nan Huang, Hsin-Hua Chen
{"title":"An optimal deep learning model for the scoring of radiographic damage in patients with ankylosing spondylitis.","authors":"Yen-Ju Chen, Der-Yuan Chen, Haw-Chang Lan, An-Chih Huang, Yi-Hsing Chen, Wen-Nan Huang, Hsin-Hua Chen","doi":"10.1177/1759720X241285973","DOIUrl":"https://doi.org/10.1177/1759720X241285973","url":null,"abstract":"<p><strong>Background: </strong>Detecting vertebral structural damage in patients with ankylosing spondylitis (AS) is crucial for understanding disease progression and in research settings.</p><p><strong>Objectives: </strong>This study aimed to use deep learning to score the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) using lateral X-ray images of the cervical and lumbar spine in patients with AS in Asian populations.</p><p><strong>Design: </strong>A deep learning model was developed to automate the scoring of mSASSS based on X-ray images.</p><p><strong>Methods: </strong>We enrolled patients with AS at a tertiary medical center in Taiwan from August 1, 2001 to December 30, 2020. A localization module was used to locate the vertebral bodies in the images of the cervical and lumbar spine. Images were then extracted from these localized points and fed into a classification module to determine whether common lesions of AS were present. The scores of each localized point were calculated based on the presence of these lesions and summed to obtain the total mSASSS score. The performance of the model was evaluated on both validation set and testing set.</p><p><strong>Results: </strong>This study reviewed X-ray image data from 554 patients diagnosed with AS, which were then annotated by 3 medical experts for structural changes. The accuracy for judging various structural changes in the validation set ranged from 0.886 to 0.985, whereas the accuracy for scoring the single vertebral corner in the test set was 0.865.</p><p><strong>Conclusion: </strong>This study demonstrated a well-trained deep learning model of mSASSS scoring for detecting the vertebral structural damage in patients with AS at an accuracy rate of 86.5%. This artificial intelligence model would provide real-time mSASSS assessment for physicians to help better assist in radiographic status evaluation with minimal human errors. Furthermore, it can assist in a research setting by offering a consistent and objective method of scoring, which could enhance the reproducibility and reliability of clinical studies.</p>","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"16 ","pages":"1759720X241285973"},"PeriodicalIF":3.4,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11459512/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142393610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The incidence of vasculitides in Israel from 2007 to 2021 and during the COVID-19 pandemic. 2007 年至 2021 年以及 COVID-19 大流行期间以色列血管病的发病率。
IF 3.4 2区 医学
Therapeutic Advances in Musculoskeletal Disease Pub Date : 2024-10-07 eCollection Date: 2024-01-01 DOI: 10.1177/1759720X241274032
Lior Zeller, Ran Ben David, Lena Novack, Ran Abuhasira, Mahmoud Abu-Shakra, Yuval Miskin, Iftach Sagy
{"title":"The incidence of vasculitides in Israel from 2007 to 2021 and during the COVID-19 pandemic.","authors":"Lior Zeller, Ran Ben David, Lena Novack, Ran Abuhasira, Mahmoud Abu-Shakra, Yuval Miskin, Iftach Sagy","doi":"10.1177/1759720X241274032","DOIUrl":"10.1177/1759720X241274032","url":null,"abstract":"<p><strong>Background: </strong>The incidence of various types of vasculitis conditions over time, specifically during coronavirus disease 2019 (COVID-19), is unknown.</p><p><strong>Objectives: </strong>We aimed to assess recent trends in vasculitides and the effect of the COVID-19 pandemic on these trends.</p><p><strong>Design: </strong>We conducted a retrospective analysis of Israel's largest Health Maintenance Organization, which covers over 4.7 million patients and represents 55% of the country.</p><p><strong>Methods: </strong>We calculated the age- and sex-adjusted incidence of giant cell arteritis (GCA), Takayasu, ANCA-associated vasculitis (AAV), IgA vasculitis, cryoglobulinemia, and Behcet's disease (BD) during 2007-2021. We analyzed associations of COVID-19 with the incidence of each of the examined conditions.</p><p><strong>Results: </strong>During 2007-2021, the adjusted annual incidence decreased from 7.9 (95% confidence interval (CI) 3.5-17.9) to 1.5 (95% CI 0.7-3.6) per 100,000 for GCA, from 5.2 (95% CI 2.7-11.1) to 1.5 (95% CI 0.7-3.3) per million for IgA vasculitis, and from 6.3 (95% CI 3.0-13.5) to 1.0 (0.5-2.5) per 100,000 for BD. The relative risks for these conditions decreased: 0.92 (95% CI 0.91-0.93), 0.93 (95% CI 0.89-0.98), and 0.90 (95% CI 0.85-0.94), respectively. The incidences of Takayasu, AAV, and cryoglobulinemia remained unchanged. The COVID-19 pandemic was not associated with changes in the incidence of any examined vasculitides.</p><p><strong>Conclusion: </strong>The incidences of GCA, IgA vasculitis, and BD decreased substantially in Israel during 15 years and were unaffected by the COVID-19 pandemic. Future studies should focus on possible environmental contributions to these findings.</p>","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"16 ","pages":"1759720X241274032"},"PeriodicalIF":3.4,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11465294/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142401391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Precision medicine in axial spondyloarthritis: current opportunities and future perspectives. 轴性脊柱关节炎的精准医疗:当前机遇与未来展望。
IF 3.4 2区 医学
Therapeutic Advances in Musculoskeletal Disease Pub Date : 2024-10-05 eCollection Date: 2024-01-01 DOI: 10.1177/1759720X241284869
Jacqueline So, Lai-Shan Tam
{"title":"Precision medicine in axial spondyloarthritis: current opportunities and future perspectives.","authors":"Jacqueline So, Lai-Shan Tam","doi":"10.1177/1759720X241284869","DOIUrl":"https://doi.org/10.1177/1759720X241284869","url":null,"abstract":"<p><p>Axial spondyloarthritis (axSpA) is a complex disease characterized by a diverse range of clinical presentations. The primary manifestation is inflammatory lower back pain, often accompanied by other clinical manifestations such as peripheral arthritis, enthesitis, uveitis, psoriasis, and inflammatory bowel disease. However, the presentation of axSpA can vary widely among patients. Despite extensive research, the precise pathogenesis of axSpA remains largely unknown. The lack of complete understanding poses challenges in subgrouping the disease, developing specific treatment approaches, and predicting treatment response. In this review, we will explore the limitations in diagnosing and treating axSpA. In addition, we will examine the current knowledge and potential opportunities provided by various omics and technological advancements in enhancing the diagnosis and personalized treatment of axSpA.</p>","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"16 ","pages":"1759720X241284869"},"PeriodicalIF":3.4,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457172/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142393611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Distinct characteristics and progression patterns of facet joint structural lesions in radiographic axial spondyloarthritis. 影像学轴性脊柱关节炎中关节面结构病变的不同特征和发展模式。
IF 3.4 2区 医学
Therapeutic Advances in Musculoskeletal Disease Pub Date : 2024-09-28 eCollection Date: 2024-01-01 DOI: 10.1177/1759720X241281201
Simin Liao, Liuquan Cheng, Zheng Zhao, Jian Zhu, Feng Huang
{"title":"Distinct characteristics and progression patterns of facet joint structural lesions in radiographic axial spondyloarthritis.","authors":"Simin Liao, Liuquan Cheng, Zheng Zhao, Jian Zhu, Feng Huang","doi":"10.1177/1759720X241281201","DOIUrl":"10.1177/1759720X241281201","url":null,"abstract":"<p><strong>Background: </strong>Both vertebral bodies and posterior elements of the vertebrae (facet joints, FJ) can engage in bone formation in radiographic axial spondyloarthritis (r-axSpA). However, little is known about the specific structural lesions and progression patterns of FJs in r-axSpA.</p><p><strong>Objectives: </strong>To identify specific lesions related to r-axSpA and to investigate the distinct progression patterns by comparing the FJ changes of r-axSpA with that of diffuse idiopathic skeletal hyperostosis (DISH), osteoarthritis (OA), and control group (CG).</p><p><strong>Design: </strong>Single-center, retrospective study. Longitudinal imaging data were retrieved and collected.</p><p><strong>Methods: </strong>Age- and sex-matched patients with complete thoracic and lumbar spine computed tomography (CT) data were included and their bilateral FJs were assessed. FJ changes were divided into erosions, ankylosis, joint-space narrowing, osteophytes, subchondral sclerosis, subchondral cysts, and vacuum phenomena. Average progressed year was defined as \"number of changed vertebrae × interval years\"/number of changed vertebrae.</p><p><strong>Results: </strong>In all, 50 patients in each group were included. Subchondral cysts and vacuum phenomena were not observed. Bilateral FJ ankylosis (FJA)/erosions in the thoracic and lumbar spine, and unilateral ankylosis/erosions in T1-4, T9-12 were significantly more common in r-axSpA. Joint-space narrowing/osteophytes/subchondral sclerosis were significantly more common in DISH and OA. FJ lesions progressed in 56.34% of vertebrae of r-axSpA. The most common pattern was \"FJ normal advanced to ankylosis\" (17.54%) which required 2.63 years. It was followed by \"erosions advanced to ankylosis\" (12.3%) which took 2.05 years, and by \"normal FJ advanced to erosions\" (11.04%) which took 2.29 years, respectively. Degenerative changes could also progress to FJ erosions/ankylosis (24.83%). The majority pattern in DISH/OA was \"FJ changes advanced to subchondral sclerosis/osteophytes/joint-space narrowing.\"</p><p><strong>Conclusion: </strong>Bilateral FJA/erosions are r-axSpA-specific lesions. The specific progression pattern for r-axSpA was \"FJ changes advanced to ankylosis/erosions.\" Repeated CT examination in intervals of at least 2 years will be more appropriate for monitoring FJ progression.</p>","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"16 ","pages":"1759720X241281201"},"PeriodicalIF":3.4,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11450570/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142381687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk of motor vehicle accidents with profound injuries in patients with ankylosing spondylitis: a nationwide, population-based cohort study. 强直性脊柱炎患者发生机动车事故并造成严重伤害的风险:一项基于全国人口的队列研究。
IF 3.4 2区 医学
Therapeutic Advances in Musculoskeletal Disease Pub Date : 2024-09-20 eCollection Date: 2024-01-01 DOI: 10.1177/1759720X241273039
Chung-Mao Kao, Wei-Li Ho, Yi-Ming Chen, Tsu-Yi Hsieh, Wen-Nan Huang, Yi-Hsing Chen, Hsin-Hua Chen
{"title":"Risk of motor vehicle accidents with profound injuries in patients with ankylosing spondylitis: a nationwide, population-based cohort study.","authors":"Chung-Mao Kao, Wei-Li Ho, Yi-Ming Chen, Tsu-Yi Hsieh, Wen-Nan Huang, Yi-Hsing Chen, Hsin-Hua Chen","doi":"10.1177/1759720X241273039","DOIUrl":"10.1177/1759720X241273039","url":null,"abstract":"<p><strong>Background: </strong>Patients with ankylosing spondylitis (AS) suffer from impaired physical activity and are prone to motor vehicle accidents (MVA), but definite instruction regarding the relationship between disease evolvement and MVA and potential risk factors is lacking.</p><p><strong>Objectives: </strong>To explore the risk factors and their impact on recorded MVA with profound injuries in AS patients with prescriptions.</p><p><strong>Design: </strong>Nationwide, population-based, matched retrospective cohort study.</p><p><strong>Methods: </strong>Using Taiwanese administrative healthcare databases, with available claims data from 2003 to 2013, we selected 30,911 newly diagnosed adult AS patients with concurrent prescriptions from 2006 to 2012 as AS patients, along with 309,110 non-AS individuals as the control group, matched in gender, age at index date and year of the index date. The risk of recorded MVA with profound injuries was compared between the two groups in terms of incidence rate ratio (IRR) and log-rank test <i>p</i>-value. Using Cox regression analysis, we studied associations between the risk and AS diagnosis.</p><p><strong>Results: </strong>The risk of recorded MVA with profound injuries in AS patients was significantly higher than in non-AS individuals, specifically 2 years after AS diagnosis (IRR, 2.00; 95% confidence interval (CI), 1.42-2.81). For patients with follow-up periods >2 years, the adjusted risk was positively associated with suburban residence (adjusted hazard ratio (aHR), 2.18; 95% CI, 1.55-3.06), rural residence (aHR, 1.89; 95% CI, 1.27-2.80), lower insured income (aHR, 1.35; 95% CI, 1.01-1.81) and recorded MVA with profound injuries before AS diagnosis (aHR, 6.16; 95% CI, 2.53-14.96). AS diagnosis (aHR, 1.81; 95% CI, 1.27-2.59) and frequency of ambulatory visits (aHR, 1.01; 95% CI, 1.004--1.02) were specific associated factors for them compared with those with follow-up periods ⩽2 years.</p><p><strong>Conclusion: </strong>For adult AS patients in Taiwan, factors such as AS disease evolution and frequent ambulatory visits for disease control in the second year of the disease course may significantly increase the risk of recorded MVA with profound injuries beyond 2 years after AS diagnosis.</p>","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"16 ","pages":"1759720X241273039"},"PeriodicalIF":3.4,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418241/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142308609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bone marrow edema in children: chronic nonbacterial osteomyelitis and its mimickers 儿童骨髓水肿:慢性非细菌性骨髓炎及其模仿者
IF 4.2 2区 医学
Therapeutic Advances in Musculoskeletal Disease Pub Date : 2024-09-19 DOI: 10.1177/1759720x241278438
Chiara Giraudo, Giulia Fichera, Anna Michielin, Francesco Zulian, Roberto Stramare, Winston J. Rennie
{"title":"Bone marrow edema in children: chronic nonbacterial osteomyelitis and its mimickers","authors":"Chiara Giraudo, Giulia Fichera, Anna Michielin, Francesco Zulian, Roberto Stramare, Winston J. Rennie","doi":"10.1177/1759720x241278438","DOIUrl":"https://doi.org/10.1177/1759720x241278438","url":null,"abstract":"Bone marrow is a highly cellular tissue undergoing significant developmental and physiologic changes with age. Indeed, with maturation from pediatric to the adult age there is a progressive, centrifugal conversion from red to yellow bone marrow. Histological characteristics of bone marrow are reflected in MR image signal. MR is therefore extremely sensitive in detecting pathological changes which are mostly characterized by increased free water causing high signal intensity on T2. Among the numerous diseases causing bone marrow edema in children chronic nonbacterial osteomyelitis (CNO) certainly has to be mentioned. This idiopathic inflammatory disorder is characterized by nonspecific migrating symptoms like skeletal pain with phases of exacerbations and relapses with alternating acute and chronic MR signs and it is often a diagnosis of exclusion. Hence, with bone marrow edema, various features at imaging should be considered to differentiate malignancies such as osseous lymphoma, osteosarcoma, and Ewing’s sarcoma as well as benign lesions like osteomyelitis, post-traumatic, or post-treatment bone marrow edema. The aim of this review is to recall the main characteristics of CNO and provide an overview of its main mimickers highlighting similarities and differences.","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"2 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142269496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Monotherapy or combination therapy in PsA: current aspects PsA的单一疗法或综合疗法:当前的问题
IF 4.2 2区 医学
Therapeutic Advances in Musculoskeletal Disease Pub Date : 2024-09-19 DOI: 10.1177/1759720x241274055
Elpida Skouvaklidou, Paraskevi Avgerou, Konstantinos D. Vassilakis, George E. Fragoulis, Nikolaos Kougkas
{"title":"Monotherapy or combination therapy in PsA: current aspects","authors":"Elpida Skouvaklidou, Paraskevi Avgerou, Konstantinos D. Vassilakis, George E. Fragoulis, Nikolaos Kougkas","doi":"10.1177/1759720x241274055","DOIUrl":"https://doi.org/10.1177/1759720x241274055","url":null,"abstract":"Psoriatic arthritis (PsA) is an immune-mediated inflammatory disease with heterogeneity regarding its clinical features, mainly affecting the skin and the musculoskeletal system; additionally, extra-musculoskeletal manifestations and comorbidities are common, adding complexity to its treatment. In the last decades, a plethora of therapeutic options have been available, including conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs), biological DMARDs (bDMARDs), and targeted synthetic DMARDs (tsDMARDs), and many recommendations have been published regarding the proper use of them in patients with PsA. In rheumatoid arthritis, the combination of conventional with bDMARDs or tsDMARDs is a common and recommended practice, whereas in PsA there is scarce data about the benefit of this combination. This review summarizes all the available data from randomized clinical trials, observational studies, and registries about the value of this therapeutic strategy.","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"23 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142258728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Knee osteoarthritis: disease burden, available treatments, and emerging options 膝关节骨关节炎:疾病负担、现有治疗方法和新出现的选择方案
IF 4.2 2区 医学
Therapeutic Advances in Musculoskeletal Disease Pub Date : 2024-09-17 DOI: 10.1177/1759720x241273009
Michael Langworthy, Vinod Dasa, Andrew I. Spitzer
{"title":"Knee osteoarthritis: disease burden, available treatments, and emerging options","authors":"Michael Langworthy, Vinod Dasa, Andrew I. Spitzer","doi":"10.1177/1759720x241273009","DOIUrl":"https://doi.org/10.1177/1759720x241273009","url":null,"abstract":"Osteoarthritis (OA) is a prevalent condition that affects nearly 528 million people worldwide, including 23% of the global population aged ⩾40, and is characterized by progressive damage to articular cartilage, which often leads to substantial pain, stiffness, and reduced mobility for affected patients. Pain related to OA is a barrier to maintaining physical activity and a leading cause of disability, accounting for 2.4% of all years lived with disability globally, reducing the ability to work in 66% of US patients with OA and increasing absenteeism in 21% of US patients with OA. The joint most commonly involved in OA is the knee, which is affected in about 60%–85% of all OA cases. The aging population and longer life expectancy, coupled with earlier and younger diagnoses, translate into a growing cohort of symptomatic patients in need of alternatives to surgery. Despite the large number of patients with knee OA (OAK) worldwide, the high degree of variability in patient presentation can lead to challenges in diagnosis and treatment. Multiple society guidelines recommend therapies for OAK, but departures from guidelines by healthcare professionals in clinical settings reflect a discordance between evidence-based treatment algorithms and routine clinical practice. Furthermore, disease-modifying pharmacotherapies are limited, and treatment for OAK often focuses solely on symptom relief, rather than underlying causes. In this narrative review, we summarize the patient journey, analyze current disease burden and nonsurgical therapy recommendations for OAK, and highlight emerging and promising therapies—such as cryoneurolysis, long-acting corticosteroids, and gene therapies—for this debilitating condition.","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"17 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142258729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信